At two or more years after starting treatment, the odds of a new diagnosis of alopecia in GLP-1 users were 37% higher than in users of so-called SGLT-2 drugs and 68% higher versus DPP-4 drugs, researchers at the University of Pennsylvania reported on Wednesday in The BMJ
Dose adjustment considerations: If gastrointestinal symptoms are severe or persistent despite these measures, contact your prescribing clinician to discuss: Slowing the dose escalation schedule Temporarily reducing the dose Taking a brief treatment pause (though this may affect weight loss progress) Switching to an alternative weight management medication if symptoms are intolerable The STEP trials demonstrated that slower dose titration can reduce the incidence and severity of gastrointestinal adverse effects
Tirzepatide activates both, offering enhanced anti-inflammatory effects
Diyabetik Nropati: Kan ekeri seviyesinin uzun sre yksek deerlerde kalmas, sinirlerin hasar grmesine ve buna bal olarak hastann bata kol, bacak ve ayaklar olmak zere vcudun eitli noktalarnda his kayb ve arlar yaamasna neden olan diyabetik nropati L-C ile azaltlabilir
Cagrilintide acts on amylin receptor complexes involving calcitonin receptor and RAMPs, while Semaglutide is a GLP-1 receptor agonist approved as Ozempic and Wegovy
